Drug Trial Radar · NCT06263231
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
333
Planned (sponsor's estimate)
Start
Jun 28, 2024
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Intensity Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- OPIS USA
- First posted
- Feb 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless contraindicated, and then a maximum of 1 additional regimen.
Conditions
- Sarcoma,Soft Tissue
Interventions
INT230-6Drug
INT230-6 is a fixed combination of cisplatin, vinblastine and SHAO.
EribulinDrug
Eribulin IV
TrabectedinDrug
Trabectedin infusion
PazopanibDrug
Pazopanib pill
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From date of randomization until the documented date of death from any cause for a period of up to 2 years, unless superiority is demonstrated sooner or 80% of deaths during the study period.
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
Mayo Clinic - Arizona
Phoenix, Arizona · Recruiting
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Sarcoma Oncology Center
Santa Monica, California · Active not recruiting
University of California Los Angeles (UCLA) - Santa Monica Cancer Care
Santa Monica, California · Recruiting
Yale School of Medicine - Smilow Cancer Hospital - Yale - New Haven Hospital Location
New Haven, Connecticut · Active not recruiting
Mayo Clinic - Florida
Jacksonville, Florida · Recruiting
Profound Research LLC
Farmington Hills, Michigan · Active not recruiting
Mayo Clinic - Rochester I
Rochester, Minnesota · Recruiting
Nebraska Methodist Hospital
Omaha, Nebraska · Recruiting
Duke Cancer Center
Durham, North Carolina · Recruiting
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio · Recruiting
University of Pennsylvania - Abramson Cancer Center
Philadelphia, Pennsylvania · Recruiting
Temple University - Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Active not recruiting
Centre Leon Berard
Lyon, France · Active not recruiting
Helios Klinikum Bad Saarow
Bad Saarow, Germany · Active not recruiting
Universitäres Krebszentrum (UCCL)
Leipzig, Germany · Active not recruiting
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain · Active not recruiting
Hospital Universitari Vall Hebron
Barcelona, Spain · Active not recruiting
Centro Integral Oncologico Clara Campal (HM CIOCC)
Madrid, Spain · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.